Media Center
White Papers

White Papers

22 Nov 16

An Exploration of Novel and Repositioned Calcium Transport Mediators as Alternative Asthma Therapeutics

This whitepaper discusses the increasing interest in using repositioned calcium transport mediators as alternative asthma therapeutics. It features information on current available treatments for asthma and trials being carried out for potential new treatments.

Request a copy
14 Nov 16

The Emerging Field of Cannabinoid-Based Products

This white paper discusses the current commercial landscape for cannabinoid-based products, and includes insight into the treatment pipeline and future prospects for key products in this category. It features analysis on cannabinoid receptors, the clinical applications of tetrahydrocannabinol and cannabidiol, and the limitations of synthetic cannabinoids. This is an essential overview for understanding the therapeutic and commercial potential of cannabinoids.

Request a copy
13 Jul 16

Introducing CBR Pharma Insights

The latest CBR Pharma Insights white paper, Accelerating your Healthcare Insights, discusses how the latest trends in generic drug approval and innovation in stem cell research and oncology will impact your business. You will also learn how the CBR offering can enable you to incorporate key commercial, regulatory and technological trends within fast-growing sectors of the life sciences industry into your decision making and planning.

Request a copy
27 Oct 15

The Obesity Landscape: Obstacles to Current and Future Weight Loss Drugs

This white paper begins by examining the impact of the global obesity epidemic by considering the economic and social cost of obesity and its related comorbidities including Type 2 Diabetes (T2D). This is followed by a discussion of the long-term safety concerns predominately on cardiovascular risk, and low reimbursement rates of weight loss drugs. The paper then assesses the implications of these barriers for future obesity therapeutics, with a focus on the overlap across obesity and T2D indications.

Request a copy
16 Sep 15

Versatile Oncology Products: One Target for Many Sites

This white paper begins with an assessment of the current status of the oncology market and pipeline, with a focus on pipeline products that have first-in-class molecular targets. This is followed by an examination of versatile first-in-class pipeline products and molecular targets, which are being developed across a number of distinct cancer sites, and illustrate the potential of certain targeted therapies in cancer to achieve compelling efficacy and safety profiles across multiple patient populations.

Request a copy